

The Burden of Surgery for Tenosynovial Giant Cell Tumor: A Targeted Review, Supplementary Material

Poster ID: SA78

Brooke Harrow,¹ Max D Lee,² Emily Kaiser,² Nicholas Zeringo¹

¹Deciphera Pharmaceuticals, LLC, Waltham, MA, USA; ²Costello Medical, Boston, MA, USA

Supplementary Table 1. Characteristics of all studies included in the review

Study	Geography	Design	Intervention of interest	N enrolled	TGCT eligibility	Outcomes included in the review
Blay 2022¹	Australia, Canada, France, Italy, The Netherlands, Poland, Spain, UK, US	Phase I/II open-label trial	Vimseltinib	58	D/L-TGCT not amenable to surgery	Humanistic, economic, treatment patterns
Cassier 2020²	France, US	Phase I open-label trial	Emactuzumab	63	D-TGCT	Humanistic, treatment patterns
Cevik 2020³	Turkey	Retrospective cohort study	Surgery (excision)	173	L-TGCT of the hand	Humanistic
Cosseddu 2022⁴	Italy	Retrospective cohort study	Surgery (open synovectomy)	20	TGCT of the knee	Economic, treatment patterns
Dai 2022⁵	US	Cross-sectional patient survey	Pexidartinib	83	NR	Economic, treatment patterns
Ebrahimipour 2022⁶	Iran	Cross-sectional national registry/database study	NR	2,593	Malignant TGCT	Epidemiology
Ehrenstein 2017⁷	Denmark	Cross-sectional national registry/database study	NR	2,661	D/L-TGCT	Epidemiology
ENLIVEN⁸	Australia, Canada, Denmark, France, Germany, Hungary, Italy, The Netherlands, Poland, Spain, UK, US	Phase III, double-blind, placebo-controlled RCT	Pexidartinib	120	D/L-TGCT not amenable to surgery	Humanistic, economic, treatment patterns
Gortzak 2018⁹	Israel	Retrospective cohort study	Surgery (arthroscopic or open synovectomy) ± adjuvant ⁹⁰ Yttrium	56	D-TGCT of the knee	Humanistic
Gu 2014¹⁰	China	Retrospective cohort study	Surgery (arthroscopic or open synovectomy)	41	D-TGCT of the knee	Humanistic
Houdek 2017¹¹	US	Retrospective cohort study	Surgery (arthroplasty)	48	D/L-TGCT of the knee	Humanistic
Kerschner 2021¹²	US	Retrospective cohort study	Surgery (arthroscopic synovectomy ± open resection)	41	D-TGCT of the knee	Humanistic
Keyhani 2018¹³	NR	NR	Surgery (arthroscopic synovectomy)	21	D-TGCT of the knee	Economic, treatment patterns
Li 2023¹⁴	China	Retrospective cohort study	Surgery (arthroplasty or arthroscopic synovectomy)	37	TGCT of the hip	Economic, treatment patterns
Lin 2023¹⁵	US	National registry/database	Any (including surgery and systemic therapy)	2,856	NR	Economic, treatment patterns

Study	Geography	Design	Intervention of interest	N enrolled	TGCT eligibility	Outcomes included in the review
Margad 2017 ¹⁶	Morocco	Retrospective cohort study	NR	20	D/L-TGCT	Epidemiology
Mastboom 2017 ¹⁷	The Netherlands	National registry/database	NR	4,138	D/L-TGCT	Epidemiology, economic, treatment patterns
Mastboom 2018 ¹⁸	Australia, Canada, The Netherlands, UK, US, Other	Cross-sectional patient survey	NR	337	D/L-TGCT	Humanistic, economic, treatment patterns
Mastboom 2020 ¹⁹	UK	Retrospective cohort study	Imatinib mesylate	25	D-TGCT of the large joints	Economic, treatment patterns
Neyisci 2020 ²⁰	Turkey	Retrospective cohort study	Surgery	552	D/L-TGCT	Economic, treatment patterns
REALIZE ²¹	Japan	Phase II, double-blind, placebo-controlled RCT	Zaltoprofen	41	D-TGCT or unresectable L-TGCT of the ankle or knee	Humanistic, economic, treatment patterns
Spierenburg 2022 ²²	Australia, France, Italy, The Netherlands	Phase II, open-label trial (nilotinib)	Nilotinib	56	D-TGCT not amenable to surgery	Economic, treatment patterns
Su 2021 ²³	China	Retrospective cohort study	Surgery (arthroplasty and synovectomy)	24	D-TGCT of the knee	Economic
Sun 2023 ²⁴	China	Retrospective cohort study	Surgery (arthroscopic synovectomy) ± tranexamic acid	80	D-TGCT of the knee	Humanistic, economic, treatment patterns
Tap 2022 ²⁵	US	Phase I open-label trial	Pexidartinib	91	D-TGCT not amenable to surgery	Economic
TOPP 2021 ²⁶	Austria, France, Germany, Italy, The Netherlands, Spain, UK, US	Retrospective cohort study	Wait-and-see, surgery, or systemic therapy	166	D-TGCT	Humanistic, economic, treatment patterns
TOPP 2021 ²⁷	Austria, France, Germany, Italy, the Netherlands, Spain	Retrospective/prospective cohort study	NR	146	D-TGCT	Humanistic, economic
TOPP 2023 ²⁸	Austria, France, Germany, Italy, The Netherlands, Spain, UK, US	Prospective cohort study	Any (including surgery, systemic therapy, and radiotherapy)	176	D/L-TGCT	Humanistic, economic, treatment patterns
van der Heijden 2016 ²⁹	Multinational	Cross-sectional patient survey	NR	1,112	D/L-TGCT	Humanistic, economic, treatment patterns
Verspoor 2014 ³⁰	The Netherlands	Retrospective cohort study	NR	104	D/L-TGCT	Humanistic

Study	Geography	Design	Intervention of interest	N enrolled	TGCT eligibility	Outcomes included in the review
Verspoor 2019³¹	The Netherlands	Prospective cohort study	Surgery (arthroscopic or open synovectomy, or endoprostheses)	206	D/L-TGCT of the large joints	Humanistic, economic, treatment patterns
Xu 2022³²	China, US	Phase I open-label trial	Pimicotinib	27	NR	Economic
Yang 2015³³	China	Retrospective cohort study	Surgery (arthroscopic or open)	47	D-TGCT of the knee	Humanistic
Zheng 2022³⁴	China	Retrospective cohort study	Surgery	78	D/L-TGCT of the knee	Humanistic, economic, treatment patterns
Zyluk 2020³⁵	Poland	Retrospective cohort study	Surgery	58	D-TGCT of the hand or wrist	Economic, treatment patterns
Zyluk 2023³⁶	Poland	Retrospective cohort study	Surgery	346	D/L-TGCT of the upper extremities	Treatment patterns

Abbreviations: (D/L)-TGCT, (diffuse/localized) tenosynovial giant cell tumor; NR, not reported; RCT, randomized controlled trial; UK, United Kingdom; US, United States.

References

1. Blay JY, Gelderblom H, Rutkowski P, et al. Patient-reported outcomes following treatment with vimseltinib for tenosynovial giant cell tumour in a phase 2 expansion study. *Value in Health* 2022;25(12 Supplement):S15.
2. Cassier PA, Italiano A, Gomez-Roca C, et al. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. *European Journal of Cancer* 2020;141:162-170.
3. Cevik HB, Kayahan S, Eceviz E, et al. Tenosynovial giant cell tumor in the foot and ankle. *Foot and Ankle Surgery* 2020;26(6):712-716.
4. Cosseddu F, Ipponi E, Ruinato AD, et al. Surgical management of villonodular-pigmented synovitis of knee: decisional algorithm. *Orthopedic Reviews* 2022;14.
5. Dai D, Lin F, Pan I, et al. Characteristics of patients receiving pexidartinib in the real-world setting: a cross-sectional survey. *Connective Tissue Oncology Society (CTOS) Annual Meeting*. Vancouver, Canada, 2022.
6. Ebrahimpour A, Chehrassan M, Sadighi M, et al. Soft tissue sarcoma of extremities: descriptive epidemiological analysis according to national population-based study. *Archives of Bone and Joint Surgery* 2022;10(1):67-77.
7. Ehrenstein V, Andersen SL, Qazi I, et al. Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in Denmark. *Journal of Rheumatology* 2017;44(10):1476-1483.
8. Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. *The Lancet* 2019;394(10197):478-487.
9. Gortzak Y, Kollender Y, Dadia S, et al. Inconclusive benefit of adjuvant ⁹⁰Yttrium hydroxyapatite to radiosynovectomy for diffuse-type tenosynovial giant-cell tumour of the knee. *Bone and Joint Journal* 2018;100B(7):984-988.
10. Gu HF, Zhang S, Zhao C, et al. A comparison of open and arthroscopic surgery for treatment of diffuse pigmented villonodular synovitis of the knee. *Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA* 2014;22(11):2830-2836.
11. Houdek MT, Scorianz M, Wyles CC, et al. Long-term outcome of knee arthroplasty in the setting of pigmented villonodular synovitis. *Knee* 2017;24(4):851-855.
12. Kerschner A, King D, Vetter C. Clinical outcomes of diffuse PVNS of the knee following arthroscopic complete synovectomy +/- posterior open resection. *Journal of Orthopaedics* 2021;28:34-40.
13. Keyhani S, Kazemi SM, Ahn JH, et al. Arthroscopic treatment of diffuse pigmented villonodular synovitis of the knee: complete synovectomy and septum removal-midterm results. *Journal of Knee Surgery* 2019;32(5):427-433.
14. Li T, Mei L, Xu Y, et al. Total hip arthroplasty or arthroscopy for pigmented villonodular synovitis of the hip: a retrospective study with 3-year follow-up at minimum. *Orthopaedic Surgery* 2023;15(6):1498-1504.
15. Lin F, Wilson K, Kwong WJ, et al. Understanding the effect of osteoarthritis on surgical treatment patterns, healthcare resource utilization, and costs among patients with tenosynovial giant cell tumors. *JAAOS: Global Research and Reviews* 2023;7:01.
16. Margad O, Boukhris J, Azriouil O, et al. Villonodular synovitis of the knee: about 20 cases. *Pan African Medical Journal* 2017;28:86.
17. Mastboom MJL, Verspoor FGM, Verschoor AJ, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. *Acta Orthopaedica* 2017;88:688-694.
18. Mastboom MJ, Planje R, van de Sande MA. The patient perspective on the impact of tenosynovial giant cell tumors on daily living: crowdsourcing study on physical function and quality of life. *Interactive Journal of Medical Research* 2018;7:e4.
19. Mastboom MJL, Lips W, van Langevelde K, et al. The effect of imatinib mesylate in diffuse-type tenosynovial giant cell tumours on MR imaging and PET-CT. *Surgical Oncology* 2020;35:261-267.

20. Neyisci C, Erdem Y. Battle against musculoskeletal tumors: descriptive data of military hospital experience. *Frontiers in Public Health* 2020;8:97.
21. Takeuchi A, Endo M, Kawai A, et al. Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: The REALIZE study. *Frontiers in Oncology* 2022;12 (no pagination).
22. Spierenburg G, Grimison P, Chevreau C, et al. Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT. *European Journal of Cancer* 2022;173:219-228.
23. Su W, Zhou Y, Lu W, et al. Short-term outcomes of synovectomy and total knee replacement in patients with diffuse-type pigmented villonodular synovitis. *Journal of Knee Surgery* 2021;34(3):247-250.
24. Sun W, Mao Y, Xiong Y, et al. The clinical effect of topical application of tranexamic acid in arthroscopic synovectomy of pigmented villonodular synovitis of the knee. *Orthopedics* 2023;46(3):E179-E185.
25. Tap WD, Singh AS, Anthony SP, et al. Results from phase I extension study assessing pexidartinib treatment in six cohorts with solid tumors including TGCT, and abnormal CSF1 transcripts in TGCT. *Clinical Cancer Research* 2022;28:298-307.
26. Bernthal NM, Spierenburg G, Healey JH, et al. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study. *Orphanet Journal Of Rare Diseases* 2021;16:191.
27. Lopez-Bastida J, Aranda-Reneo I, Rodriguez-Sanchez B, et al. Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry. *Orphanet Journal of Rare Diseases* 2021;16(1) (no pagination).
28. Palmerini E, Healey JH, Bernthal NM, et al. Tenosynovial giant cell tumor observational platform project (TOPP) registry: a 2-year analysis of patient-reported outcomes and treatment strategies. *Oncologist* 2023;28(6):E425-E435.
29. van der Heijden L, Piner SR, van de Sande MAJ. Pigmented villonodular synovitis: a crowdsourcing study of two hundred and seventy two patients. *International Orthopaedics* 2016;40(12):2459-2468.
30. Verspoor FG, Zee AA, Hannink G, et al. Long-term follow-up results of primary and recurrent pigmented villonodular synovitis. *Rheumatology (Oxford)* 2014;53:2063-70.
31. Verspoor FGM, Mastboom MJL, Hannink G, et al. The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function. *Bone & Joint Journal* 2019;101-B:272-280.
32. Xu H, Li B, Luo Y, et al. Preliminary phase 1b results of ABSK021 for advanced tenosynovial giant cell tumor: significant antitumor activity and favourable safety profile. *Connective Tissue Oncology Society (CTOS) Annual Meeting*. Vancouver, Canada, 2022.
33. Yang B, Liu D, Lin J, et al. Surgical treatment of diffuse pigmented villonodular synovitis of the knee. *Chung-Kuo i Hsueh Ko Hsueh Yuan Hsueh Pao Acta Academiae Medicinae Sinicae* 2015;37:234-9.
34. Zheng K, Yu XC, Hu YC, et al. A new simple and practical clinical classification for tenosynovial giant cell tumors of the knee. *Orthopaedic Audio-Synopsis Continuing Medical Education [Sound Recording]* 2022;14:290-297.
35. Zyluk A, Owczarska A. Outcomes of surgery for giant cell tumors of the tendon sheath within the hand. *Polski Przegląd Chirurgiczny* 2020;92:16-21.
36. Zyluk A, Owczarska A. Outcomes of Surgery for benign tumours in the upper extremity. *Handchirurgie, Mikrochirurgie, Plastische Chirurgie* 2023;09:09.